No Data
Haichuang Pharmaceutical Co., Ltd. 2024 Annual Report
2024 Annual Report Summary
Haichuang Pharmaceutical (688302.SH) announced its 2024 annual performance, with a net loss attributable to the parent company of 0.199 billion yuan, a reduced loss.
Haichuang Pharmaceutical (688302.SH) released its annual report for 2024, with the company's revenue for the year 2024 at 36...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Haichuang Pharmaceutical (688302.SH): 8.7907 million restricted shares will be unlocked on April 14.
On April 3, Gelonghui reported that Haichuang Pharmaceutical (688302.SH) announced that the total number of Stocks listed for circulation this time is 8.7907 million shares. The date for Stocks to be listed for circulation is April 14, 2025 (due to April 12, 2025, being a non-trading day, it is postponed to the next trading day).
Shareholder Yingchuang Dpower has completed a Shareholding reduction of 2.38% in Haichuang Pharmaceutical (688302.SH).
Haichuang Pharmaceutical (688302.SH) announced that as of March 25, 2025, the timeline for this Shareholding reduction plan...